Retension Pharmaceuticals IPO: Date, Status and What We Know
FiledUnited States · Nasdaq Capital MarketRTSN
IPO facts
- Status
- Filed
- Market
- United States
- Country
- United States
- Exchange
- Nasdaq Capital Market
- Ticker
- RTSN
- Sector
- Biopharmaceuticals (cardiovascular)
- Filing date
- First trading day
- Not announced
- Price range
- Not announced
- Offering size
- Not announced
- Last valuation
- Not announced
About Retension Pharmaceuticals
Retension Pharmaceuticals is a clinical-stage biopharmaceutical company developing RTN-001, a once-daily oral PDE-5 inhibitor intended to lower blood pressure in hypertension and related cardiovascular diseases.
IPO notes
Retension Pharmaceuticals publicly filed its Form S-1 on 18 September 2026. It has applied to list its common stock on the Nasdaq Capital Market under RTSN; the filing leaves the number of shares and the price range blank (sec.gov). No pricing date had been announced as of 5 October 2026.
Other IPOs in this market
Sources
- sec.gov · Form S-1 registration statement ·
Named as plain text with what each source states and the date it was checked.